

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT7847500

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	ABBVIE OVERSEAS S.Á.R.L.	12/21/2020
RECEIVING PARTY DATA		
Name:	ABBVIE GLOBAL LIMITED	
Street Address:	16 CHURCH STREET	
Internal Address:	4TH FLOOR, WASHINGTON HOUSE	
City:	HAMILTON	
State/Country:	BERMUDA	
Postal Code:	HM11	
PROPERTY NUMBERS Total: 1		
	Property Type	Number
	Patent Number:	10844041
CORRESPONDENCE DATA		
Fax Number:		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	4142775000	
Email:	pat-dept@quarles.com, meighan.flanigan@quarles.com	
Correspondent Name:	QUARLES & BRADY LLP	
Address Line 1:	411 E. WISCONSIN AVE	
Address Line 2:	SUITE 2400	
Address Line 4:	MILWAUKEE, WISCONSIN 53202	
ATTORNEY DOCKET NUMBER:	154561.00387_ABV12400USC1	
NAME OF SUBMITTER:	MEIGHAN M. FLANIGAN	
SIGNATURE:	/Meighan M. Flanigan/	
DATE SIGNED:	03/15/2023	
Total Attachments: 30		
source=154561-00044-ABV12109USO1-2020_12_21_Agreement-AbbVie Overseas to AbbVie Global Limited with Exhibit A#page1.tif		
source=154561-00044-ABV12109USO1-2020_12_21_Agreement-AbbVie Overseas to AbbVie Global Limited with Exhibit A#page2.tif		

Exhibit A#page29.tif

source=154561-00044-ABV12109USO1-2020_12_21_Agreement-AbbVie Overseas to AbbVie Global Limited with
Exhibit A#page30.tif

PATENT

REEL: 063100 FRAME: 0019

CONTRIBUTION AND ASSUMPTION AGREEMENT

This Contribution and Assumption Agreement ("**Agreement**") is made and entered into as of December 21, 2020 (the "**Effective Date**") by and between ABBVIE OVERSEAS S.À R.L., a private limited liability company (*société à responsabilité limitée*) organized under the laws of the Grand Duchy of Luxembourg, having its registered office at 26, boulevard Royal, L-2449 Luxembourg, Grand Duchy of Luxembourg and registered with the Luxembourg Register of Trade and Companies (*R.C.S. Luxembourg*) under number B167837 ("**Parent**"), and ABBVIE GLOBAL LIMITED, an exempted company limited by shares organized and existing under the laws of Bermuda, having its registered office at 4th Floor, Washington House, 16 Church Street, Hamilton, HM11, Bermuda ("**Subsidiary**").

RECITALS

A. Subsidiary became wholly-owned by Parent pursuant to that certain share contribution agreement made and entered into as of the Effective Date by and between AbbVie International S.à r.l., a Luxembourg private limited liability company, and Parent.

B. Parent and Subsidiary are owned indirectly by AbbVie Inc., a Delaware corporation ("**AbbVie**") that is the parent of a global group of affiliates.

C. Parent desires to contribute, transfer, assign and novate the Contributed Assets (as defined below) to Subsidiary as a gratuitous contribution to Subsidiary's contributed surplus account which for greater certainty will not result in Subsidiary issuing any consideration, including shares or securities convertible into shares, or incurring repayment obligations of any kind in connection with such contribution, on the terms and conditions of this Agreement. In connection with the contribution of the Contributed Assets, Parent is also willing to transfer and assign the Post-Effective Date Obligations (as defined below) to Subsidiary, on the terms and conditions of this Agreement.

D. Subsidiary is willing to accept the contribution, transfer, assignment and novation of the Contributed Assets as a gratuitous contribution to Subsidiary's contributed surplus account, on the terms and conditions of this Agreement. In connection with the contribution of the Contributed Assets, Subsidiary is also willing to accept and assume the Post-Effective Date Obligations, on the terms and conditions of this Agreement.

E. Parent and Subsidiary are entering into this Agreement to document and effectuate the contribution, transfer and assignment of the Contributed Assets by Parent to Subsidiary and the transfer and assignment of the Post-Effective Date Obligations by Parent to Subsidiary.

F. The contribution, transfer, assignment and novation of the Contributed Assets and the transfer and assignment of the Post-Effective Date Obligations are part of a restructuring undertaken to realign intellectual property owned by certain wholly-owned subsidiaries of AbbVie, including, but not limited to, Parent.

G. Following the transfer and assignment of the Contributed Assets, Subsidiary will have primary responsibility for further development and commercialization of the Contributed Assets, so as to facilitate the efficient management of the Contributed Assets and otherwise improve operational efficiency.

NOW, THEREFORE, in consideration of the mutual covenants and agreements set forth below, the Parties hereby agree as follows:

1. DEFINED TERMS

As used in this Agreement, the following terms shall have the following meanings:

(a) **"Action"** means any legal or administrative proceeding, suit, claim, audit, investigation, arbitration, mediation or action.

(b) **"Affiliate"** means any corporation, firm, partnership, limited liability company or other entity, whether *de jure* or *de facto*, that directly or indirectly owns, is owned by, or is under common ownership with a Party, to the extent of at least fifty percent (50%) of the equity having the power to vote on or direct the affairs of the entity, and any person, firm, partnership, corporation, limited liability company or other entity actually controlled by, controlling, or under common control with a Party; provided, however, that the term "Affiliate" shall not include either Party.

(c) **"Contributed Assets"** means the Intellectual Property Rights, the Transferred Agreements and other assets described on **Exhibit A** hereto, *provided, however,* that in no event shall the Contributed Assets include the Excluded Assets.

(d) **"Excluded Assets"** means all assets of Parent other than the Contributed Assets.

(e) **"Excluded Obligations"** means all liabilities and obligations of Parent other than the Post-Effective Date Obligations. Excluded Obligations includes in particular all liabilities and obligations of Parent accrued for on the balance sheet of Parent prior to the Effective Date.

(f) **"Intellectual Property Rights"** means the following rights, whether now or hereafter existing, acquired, filed, issued, perfected, registered or recorded by Parent, including, without limitation:

(i) any and all inventions, invention disclosures, discoveries, and improvements, whether or not patentable;

(ii) any and all **"Patents"**, the term Patents to include: (1) priority rights and rights to claim priority; (2) applications for provisional, national, regional and international patents, certificates of invention, and all applications claiming priority therefrom, including, converted provisionals, continuations, continuations-in-part, divisionals, and continued prosecution applications; (3) national patents issued or granted from the foregoing (2), including utility patents, utility models, petty patents, design patents and certificates of invention, (4) extensions or restorations by existing of future extension or restoration mechanisms, including reexaminations, revalidations, reissues, supplementary protection certificates, pediatric exclusivity periods, and the like of the foregoing (2) and (3), (5) similar rights, including so-called pipeline protection, confirmation, or registration patent or patent of addition of the foregoing (2) and (3);

(iii) all rights to publish cautionary notices reserving ownership of said subject matter;

(iv) all rights to register said Patents in appropriate registries throughout the world;

(v) any and all rights in and to works of authorship and rights associated with works of authorship (collectively, "**Copyrights**"), including without limitation: (1) copyrights, rights in and to copyright applications and copyright registrations, respectively issued or filed throughout the world; (2) moral rights or rights to claim authorship to or to object to any distortion, mutilation, or other modification or other derogatory action in relation to a work, whether or not such would be prejudicial to the author's reputation, and any similar right existing under common or statutory law of any country in the world or under any treaty, regardless of whether or not such right is denominated or generally referred to as a "moral right"; (3) any and all rights to prosecute, register, obtain or maintain copyright applications, registrations or extensions for any of the foregoing; and (4) the right to sue in its own name and recover damages for past, present or future infringement or misappropriation of any of the foregoing;

(vi) any and all worldwide rights in and to any and all trademarks, service marks, trade names, trade dress, logos, designs and slogans, in word mark, stylized design and/or any other format, and domain names (collectively, "**Trademarks**"), including without limitation any and all rights in and to any registrations of, or applications for, any of the foregoing items, and including without limitation: (1) any and all common law trademarks and service marks; (2) any and all of the goodwill of the business associated with and symbolized by the foregoing items; and (3) the right to sue in its own name and recover damages for past, present or future infringement or misappropriation of any of the foregoing;

(vii) any and all rights relating to trade secrets, including without limitation: (1) those trade secrets defined in the Uniform Trade Secrets Act and under any corresponding foreign or state statutory or common law; (2) any and all rights in and to confidential business, technical and know-how information; and (3) the right to sue in its own name and recover damages for past, present or future infringement or misappropriation of any of the foregoing;

(viii) any and all proprietary information, know-how, materials and technology related to any of the foregoing;

(ix) any and all goodwill associated with or symbolized by the foregoing items; and

(x) the right to sue in its own name and recover damages for past, present or future infringement or misappropriation of any of the foregoing (i) through (ix).

(g) "**Party**" means either Parent or Subsidiary and "**Parties**" means Parent and Subsidiary collectively.

(h) "**Post-Effective Date Obligations**" means the following liabilities and obligations:

(i) of Parent related to the ownership, operation or use of the Contributed Assets from and after the Effective Date, including, without limitation, all liabilities and obligations of Parent arising under the Transferred Agreements for an occurrence or event or actions taken or failed to be taken from and after the Effective Date under such Transferred Agreements; and

(ii) arising out of claims made by any Third Party in any Action against Parent after the Effective Date to the extent relating to, arising out of or resulting from (A) the Contributed Assets or the Post-Effective Date Obligations referred to in clause (i) above and (B) an occurrence or event happening after the Effective Date;

provided, however, that in no event shall the Post-Effective Date Obligations include the Excluded Obligations.

(i) **"Products or Compounds"** means the products or compounds listed on Exhibit B attached hereto.

(j) **"Third Party" or "Third Parties"** means any person or entity other than a Party or an Affiliate of a Party.

2. CONTRIBUTION, TRANSFER AND ASSIGNMENT OF CONTRIBUTED ASSETS

2.1 Contribution by Parent. Subject to Section 10, as of the Effective Date Parent hereby contributes, transfers, assigns, novates and conveys to Subsidiary all of Parent's rights, title and interest in and to the Contributed Assets as an irrevocable, non-refundable and unconditional gratuitous contribution to Subsidiary's contributed surplus account; no form of consideration will be paid and the contribution, transfer, assignment and novation of the Contributed Assets will not result in the issuance of any shares by Subsidiary to Parent or the grant by Subsidiary of any rights to Parent. In connection with the contribution of the Contributed Assets, Parent also hereby transfers, assigns and novates the Post-Effective Date Obligations to Subsidiary.

2.2 Acceptance by Subsidiary. Subject to Section 10, as of the Effective Date, Subsidiary hereby accepts the contribution, transfer, assignment, novation and conveyance of the Contributed Assets as an irrevocable, non-refundable and unconditional gratuitous contribution to Subsidiary's contributed surplus account by Parent, its sole shareholder, without any form of consideration paid nor any issuance of shares by Subsidiary to Parent. As of the Effective Date, Subsidiary hereby accepts and assumes the Post-Effective Date Obligations.

2.3 Treatment of Contribution in Kind - No Gift. The Parties agree that the contribution of the Contributed Assets, shall be recorded by Subsidiary as a gratuitous capital contribution from its sole shareholder and that no additional shares shall be issued to Parent in consideration of or in connection with this Agreement and/or the contribution, transfer, assignment, novation and conveyance of the Contributed Assets to Subsidiary. The contribution of the Contributed Assets does not constitute and shall not be qualified as a gift made by Parent to Subsidiary since this contribution is implemented to a wholly-owned subsidiary of Parent and is made exclusively in consideration for the economic interest of Parent.

2.4 Rights Included. This contribution, transfer and assignment includes the right to sue for past, present and future infringement and/or misappropriation claims with respect to the Contributed Assets. Without limiting the foregoing, the Parties acknowledge and agree that all current and future rights of Parent arising under or related to each of the Transferred Agreements, including without limitation any right to receive payments thereunder and the right to sue in the name of Parent (or any of its predecessors or assignors) or in the name of Subsidiary for past, present and future infringement and/or misappropriation claims and recover damages and the right to recover damages for past, present or future breaches or defaults under each of the Transferred Agreements, are hereby contributed and assigned by Parent to Subsidiary as of the Effective Date.

3. WARRANTY BY PARENT

Parent represents and warrants to Subsidiary that Parent has the right to transfer the Contributed Assets to Subsidiary. On the Effective Date Parent hereby conveys good and marketable title to Subsidiary with respect to those Contributed Assets to which Parent holds title. On the Effective Date, Parent hereby conveys to Subsidiary all of Parent's rights and interests in and to those Contributed Assets to which Parent holds beneficial or other rights thereto.

4. "AS IS" CONDITION OF CONTRIBUTED ASSETS

EXCEPT FOR THE FOREGOING WARRANTY OF PARENT, THE CONTRIBUTED ASSETS ARE BEING CONTRIBUTED, TRANSFERRED, ASSIGNED AND CONVEYED TO SUBSIDIARY IN "AS IS" CONDITION, WITHOUT ANY EXPRESS, IMPLIED OR STATUTORY WARRANTIES OF ANY KIND, INCLUDING, BUT NOT LIMITED TO, ANY IMPLIED WARRANTIES OF MERCHANTABILITY, OPERABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT OF THIRD PARTY RIGHTS, AND THOSE ARISING FROM A COURSE OF DEALING, USAGE OR TRADE PRACTICE.

5. BULK SALES LAWS

Each Party waives compliance with any applicable bulk sales law and any other similar laws in any applicable jurisdictions in respect of the transactions contemplated by this Agreement, including without limitation any applicable tax law that may require notification of tax authorities and related actions in respect of transfers of assets outside of the ordinary course of business.

6. POST-EFFECTIVE DATE OBLIGATIONS

Subject to Section 10, following the transfers described in Section 2 of this Agreement, Subsidiary shall be fully and solely responsible for the Post-Effective Date Obligations, and Subsidiary does hereby expressly accept full and sole responsibility for the Post-Effective Date Obligations as of the Effective Date. If Parent, on the one hand, or Subsidiary, on the other hand, after the Effective Date receives any funds properly belonging to the other Party in accordance with the terms of this Agreement, the receiving Party will promptly so advise such other Party, will segregate and hold such funds in trust for the benefit of such other Party and will promptly deliver such funds, together with any interest earned thereon, to an account or accounts designated in writing by such other Party. If any Action is finally determined or settled following the Effective Date that relates

to occurrences or events occurring prior to and after the Effective Date, Parent shall be entitled to any amounts recovered from and be responsible for amounts payable to a Third Party to the extent attributable to the occurrence or event occurring prior to the Effective Date.

7. INDEMNIFICATION

Subsidiary shall indemnify and hold harmless Parent, its managers, officers, shareholders, representatives and agents from and against any and all Third Party claims, losses, damages, demands, liabilities, obligations, actions and causes of action, of any kind or nature whatsoever in law or in equity, arising out of or related to the Post-Effective Date Obligations.

Parent shall indemnify and hold harmless Subsidiary, its directors, officers, shareholders, representatives and agents from and against any and all Third Party claims, losses, damages, demands, liabilities, obligations, actions and causes of action, of any kind or nature whatsoever in law or in equity, arising out of or related to the Excluded Obligations.

8. FURTHER ASSURANCES

Parent hereby covenants and agrees to take such further actions and execute such additional documents as may be reasonably requested by Subsidiary to further effect the contributions, transfers, assignments and conveyances of the Contributed Assets as set forth in this Agreement. Subsidiary hereby covenants and agrees to take such further actions and execute such additional documents as may be reasonably requested by Parent to further effect the provisions set forth in this Agreement. The Parties shall complete Schedules 1 - 2 within 180 days of the Effective Date.

9. NON-ASSIGNABLE ASSETS

It is the intention of the Parties that the contribution of the Contributed Assets shall be effective as of the Effective Date, from and after which date Subsidiary shall be the beneficial owner of the Contributed Assets for all purposes and that all the benefits and burdens of ownership of the Contributed Assets shall transfer to Subsidiary on the Effective Date. Notwithstanding anything in this Agreement to the contrary, however, this Agreement shall not constitute a contribution or transfer of any Contributed Asset if an attempted contribution, transfer or assignment thereof would constitute a breach or other contravention of any agreement with any Third Party, or violate any applicable law, rule, regulation, or order of any court, legislative body or governmental agency, or in any way adversely affect the rights of Parent with respect to such Contributed Asset. To the extent any transfers contemplated by this Agreement have not been fully effected on or before the Effective Date, Parent and Subsidiary shall cooperate and use commercially reasonable efforts to obtain any necessary consents or approvals or take any other actions necessary to effect such transfers as promptly as practicable following the Effective Date. If an attempted contribution or transfer of a Contributed Asset would be ineffective or would adversely affect the rights of Subsidiary such that it would not in fact receive all such Contributed Assets, then Parent instead will cooperate to provide Subsidiary with the economic and commercial benefits of such Contributed Asset. Parent, at Subsidiary's expense, will enforce for the benefit of Subsidiary any rights of Parent against a Third Party with respect to any such non-assignable or non-transferable Contributed Asset.

Each Contributed Asset is contributed and accepted, as the case may be, subject to any pre-existing rights or encumbrances.

10. REPRESENTATIONS AND WARRANTIES REGARDING AUTHORITY

Each Party represents and warrants to the other Party that (a) it has full power, authority and legal right to execute and deliver this Agreement and to perform its obligations hereunder, and (b) this Agreement constitutes its legal, valid and binding obligation, enforceable against such Party in accordance with its terms.

11. MISCELLANEOUS PROVISIONS

11.1 Entire Agreement. The Parties acknowledge that this Agreement, together with its Exhibits and Schedules, evidences the complete, final and exclusive embodiment of the Parties' understanding and agreement with respect to the contribution, transfer and assignment of the Contributed Assets by Parent to Subsidiary. The Parties acknowledge and agree that (a) only the Contributed Assets, and no other assets, interests or rights of Parent, are being contributed, transferred, assigned or delivered to Subsidiary pursuant to this Agreement, and (b) Subsidiary shall only be responsible for the Post-Effective Date Obligations, and Subsidiary shall not be responsible for any other liabilities or obligations of Parent.

11.2 Amendment. This Agreement may not be altered or amended except by a written instrument executed by authorized representatives on behalf of each of the Parties.

11.3 Governing Law; Disputes. The laws of Delaware (excluding its rules governing conflicts of laws that may require an application of a different law) shall govern the construction, interpretation and other matters arising out of or in connection with this Agreement (whether arising in contract, tort, equity or otherwise), except to the extent that mandatory provisions of other jurisdictions apply to the sale, transfer and assignment of the Contributed Assets. Any Action or proceeding arising out of or relating to this Agreement or the transactions contemplated by this Agreement must be brought in the Court of Chancery or the Superior Court of the State of Delaware in and for New Castle County, Delaware (unless the federal courts have exclusive jurisdiction over the matter, in which case the United States District Court for the District of Delaware) and not in any other State or Federal court in the United States of America or any court in any other country. Each of the Parties knowingly, voluntarily and irrevocably submits to the exclusive jurisdiction of each such court in any such Action or proceeding and waives any objection it may now or hereafter have to venue or to convenience of forum.

11.4 Severability. The invalidity or unenforceability of any provision of this Agreement shall not affect the validity or enforceability of any other provision and, if possible, the invalid or unenforceable provision shall be reformed and deemed modified to be consistent with the Parties' essential purpose of contributing, transferring and assigning to Subsidiary all rights and obligations of Parent arising under or related to the Contributed Assets.

11.5 Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the Parties and their respective successors and assigns.

11.6 Counterparts. This Agreement may be executed in counterparts and, upon delivery of counterparts that together show the execution by each of the Parties, shall constitute one agreement which shall be binding upon the Parties.

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their respective duly authorized representatives, and made effective as of the Effective Date.

ABBVIE OVERSEAS S.À R.L.

ABBVIE GLOBAL LIMITED

By: Elzbieta Szlaga

Name: Elzbieta Szlaga

Title: Category A Manager

By: _____

Name: Jonathan C. Clipper

Title: Director

4668655

SIGNATURE PAGE TO CONTRIBUTION AGREEMENT

IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their respective duly authorized representatives, and made effective as of the Effective Date.


ABBVIE OVERSEAS S.À R.L.

ABBVIE GLOBAL LIMITED

By: _____

Name: Elzbieta Szlaga

Title: Category A Manager

By: _____

Name: Jonathan C. Clipper

Title: Director

4668655

SIGNATURE PAGE TO CONTRIBUTION AGREEMENT

PATENT
REEL: 063100 FRAME: 0029

EXHIBIT A

CONTRIBUTED ASSETS

1. All Intellectual Property Rights related to the Products or Compounds, as such Intellectual Property Rights exist as of the Effective Date, including the Patents listed in Schedule 1 and the Trademarks listed in Schedule 2.
2. All rights, interests and claims as of the Effective Date to all clinical study data, reports and analyses, regulatory applications, approvals and licenses, information prepared in connection with obtaining approval, and product and marketing registrations related to the Products or Compounds.
3. All rights, interests and claims of Transferor arising under or pursuant to any agreements related to the Products or Compounds, including, but not limited to, those listed on Exhibit C hereto (the "Transferred Agreements") to the extent effective as of the Effective Date.

SCHEDULE 1
Patents

Case Ref Number	Country	Application Number	Application Date	Patent Number	Grant Date	Status
ABV12109ALO1	Albania - (AL)	AL/P/2020/0689	10/28/2015	9496	9/9/2020	Granted - (G)
ABV12109ARO1	Argentina - (AR)	20150103536	10/30/2015			Filed - (F)
ABV12109ATO1	Austria - (AT)	15854320.7	10/28/2015	E 1310698	9/9/2020	Granted - (G)
ABV12109AUO1	Australia - (AU)	2015339336	10/28/2015	2015339336	1/23/2020	Granted - (G)
ABV12109BEO1	Belgium - (BE)	15854320.7	10/28/2015	3212189	9/9/2020	Granted - (G)
ABV12109BGO1	Bulgaria - (BG)	15854320.7	10/28/2015	3212189	9/9/2020	Granted - (G)
ABV12109BRO1	Brazil - (BR)	BR1120170087901	10/28/2015			Filed - (F)
ABV12109CAO1	Canada - (CA)	2965981	10/28/2015			Filed - (F)
ABV12109CHO1	Switzerland - (CH)	15854320.7	10/28/2015	3212189	9/9/2020	Granted - (G)
ABV12109CLO1	Chile - (CL)	01061-2017	10/28/2015			Filed - (F)
ABV12109CNO1	China - (CN)	201580071713.X	10/28/2015	201580071713.X	2/9/2021	Granted - (G)
ABV12109COO1	Colombia - (CO)	NC2017/0005421	10/28/2015	35093	4/22/2019	Granted - (G)
ABV12109CRO1	Costa Rica - (CR)	2017-0227	10/28/2015			Filed - (F)
ABV12109CYO1	Cyprus - (CY)	15854320.7	10/28/2015	3212189	9/9/2020	Granted - (G)
ABV12109CZO1	Czechia - (CZ)	15854320.7	10/28/2015	3212189	9/9/2020	Granted - (G)
ABV12109DEO1	Germany - (DE)	15854320.7	10/28/2015	602015058945.9	9/9/2020	Granted - (G)
ABV12109DKO1	Denmark - (DK)	15854320.7	10/28/2015	3212189	9/9/2020	Granted - (G)
ABV12109DOO1	Dominican Republic - (DO)	P2017-0104	10/28/2015			Filed - (F)
ABV12109ECO1	Ecuador - (EC)	IEPI-2017-33565	10/28/2015			Filed - (F)

ABV12109EE01	Estonia - (EE)	15854320.7	10/28/2015	3212189	9/9/2020	Granted - (G)
ABV12109EPD1	European Patent Convention - (EP)					Docketed - (D)
ABV12109EPO1	European Patent Convention - (EP)	15854320.7	10/28/2015	3212189	9/9/2020	Granted - (G)
ABV12109ESO1	Spain - (ES)	15854320.7	10/28/2015	3212189	9/9/2020	Granted - (G)
ABV12109FIO1	Finland - (FI)	15854320.7	10/28/2015	3212189	9/9/2020	Granted - (G)
ABV12109FRO1	France - (FR)	15854320.7	10/28/2015	3212189	9/9/2020	Granted - (G)
ABV12109GBO1	United Kingdom of Great Britain and Northern Ireland - (GB)	15854320.7	10/28/2015	3212189	9/9/2020	Granted - (G)
ABV12109GCO1	Gulf Cooperation Council - (GC)	2015/30282	10/29/2015			Filed - (F)
ABV12109GRO1	Greece - (GR)	20200403060	10/28/2015	3105385	9/9/2020	Granted - (G)
ABV12109GTO1	Guatemala - (GT)	A-2017-000092	10/28/2015			Filed - (F)
ABV12109HKO1	Hong Kong - (HK)	17109345.4	9/14/2017	1246635	5/14/2021	Granted - (G)
ABV12109HRO1	Croatia - (HR)	P20201666	10/28/2015	P20201666	9/9/2020	Granted - (G)
ABV12109HUO1	Hungary - (HU)	15854320.7	10/28/2015	E052373	9/9/2020	Granted - (G)
ABV12109IDO1	Indonesia - (ID)	P00201703381	10/28/2015			Filed - (F)
ABV12109IEO1	Ireland - (IE)	15854320.7	10/28/2015	3212189	9/9/2020	Granted - (G)
ABV12109ILO1	Israel - (IL)	251996	10/28/2015	251996	9/1/2020	Granted - (G)
ABV12109INO1	India - (IN)	201717015365	10/28/2015			Filed - (F)
ABV12109ISO1	Iceland - (IS)	15854320.7	10/28/2015	3212189	9/9/2020	Granted - (G)
ABV12109ITO1	Italy - (IT)	502020000106748	10/28/2015	3212189	9/9/2020	Granted - (G)
ABV12109JPO1	Japan - (JP)	2017-542792	10/28/2015	6676646	3/16/2020	Granted - (G)
ABV12109KRO1	Korea, Republic of - (KR)	10-2017-7014811	10/28/2015			Filed - (F)

ABV12109LO1	Liechtenstein - (LI)	15854320.7	10/28/2015	3212189	9/9/2020	Granted - (G)
ABV12109LTO1	Lithuania - (LT)	15854320.7	10/28/2015	3212189	9/9/2020	Granted - (G)
ABV12109LUO1	Luxembourg - (LU)	15854320.7	10/28/2015	3212189	9/9/2020	Granted - (G)
ABV12109LVO1	Latvia - (LV)	15854320.7	10/28/2015	3212189	9/9/2020	Granted - (G)
ABV12109MCO1	Monaco - (MC)	15854320.7	10/28/2015	3212189	9/9/2020	Granted - (G)
ABV12109MKO1	North Macedonia - (MK)	P-2020/819	10/28/2015	3212189	9/9/2020	Granted - (G)
ABV12109MTO1	Malta - (MT)	15854320.7	10/28/2015	3212189	9/9/2020	Granted - (G)
ABV12109MXO1	Mexico - (MX)	MX/a/2017/005681	10/28/2015	366556	7/12/2019	Granted - (G)
ABV12109MYO1	Malaysia - (MY)	PI2017701450	10/28/2015			Filed - (F)
ABV12109NLO1	Netherlands - (NL)	15854320.7	10/28/2015	3212189	9/9/2020	Granted - (G)
ABV12109NOO1	Norway - (NO)	15854320.7	10/28/2015	3212189	9/9/2020	Granted - (G)
ABV12109NZO1	New Zealand - (NZ)	731254	10/28/2015			Filed - (F)
ABV12109PAO1	Panama - (PA)	91611	10/28/2015			Filed - (F)
ABV12109PEO1	Peru - (PE)	000764-2017	10/28/2015			Filed - (F)
ABV12109PHO1	Philippines - (PH)	1-2017-500797	10/28/2015			Filed - (F)
ABV12109PKO1	Pakistan - (PK)	690/2015	10/29/2015			Filed - (F)
ABV12109PLO1	Poland - (PL)	15854320.7	10/28/2015	3212189	9/9/2020	Granted - (G)
ABV12109PTO1	Portugal - (PT)	15854320.7	10/28/2015	3212189	9/9/2020	Granted - (G)
ABV12109ROO1	Romania - (RO)	15854320.7	10/28/2015	3212189	9/9/2020	Granted - (G)
ABV12109RSO1	Serbia - (RS)	P-2020/1328	10/28/2015	61267	9/9/2020	Granted - (G)
ABV12109RUO1	Russian Federation - (RU)	2017118552	10/28/2015	2718060	3/30/2020	Granted - (G)

ABV12109SE01	Sweden - (SE)	15854320.7	10/28/2015	3212189	9/9/2020	Granted - (G)
ABV12109SG01	Singapore - (SG)	11201703391V	10/28/2015	11201703391V	5/9/2018	Granted - (G)
ABV12109SIO1	Slovenia - (SI)	201531390	10/28/2015	3212189	9/9/2020	Granted - (G)
ABV12109SKO1	Slovakia - (SK)	15854320.7	10/28/2015	3212189	9/9/2020	Granted - (G)
ABV12109SMO1	San Marino - (SM)	SM-T-202000664	10/28/2015	3212189	9/9/2020	Granted - (G)
ABV12109THO1	Thailand - (TH)	1701002334	10/28/2015			Filed - (F)
ABV12109TRO1	Turkey - (TR)	15854320.7	10/28/2015	TR202017512T4	9/9/2020	Granted - (G)
ABV12109TWO1	Taiwan (Province of China) - (TW)	104135934	10/30/2015	1691496	4/21/2020	Granted - (G)
ABV12109UAO1	Ukraine - (UA)	a201705277	10/28/2015	122965	1/27/2021	Granted - (G)
ABV12109USO1	United States of America - (US)	14/925649	10/28/2015	9642831	5/9/2017	Granted - (G)
ABV12109UYO1	Uruguay - (UY)	36379	10/30/2015			Filed - (F)
ABV12109VNO1	Vietnam - (VN)	1-2017-01979	10/28/2015			Filed - (F)
ABV12109ZAO1	South Africa - (ZA)	2017/03075	10/28/2015	2017/03075	11/28/2018	Granted - (G)
ABV12189ALO1	Albania - (AL)	AL/P/2018/0371	4/23/2015	7423	3/21/2018	Granted - (G)
ABV12189ARO1	Argentina - (AR)	20150101224	4/23/2015			Filed - (F)
ABV12189ATO1	Austria - (AT)	15721089.9	4/23/2015	3134430	3/21/2018	Granted - (G)
ABV12189AUD1	Australia - (AU)	2018271369	11/30/2018	2018271369	4/16/2020	Granted - (G)
ABV12189AUO1	Australia - (AU)	2015249649	4/23/2015	2015249649	1/17/2019	Granted - (G)
ABV12189BAO1	Bosnia and Herzegovina - (BA)	15721089.9	4/23/2015	3134430	3/21/2018	Granted - (G)
ABV12189BEO1	Belgium - (BE)	15721089.9	4/23/2015	3134430	3/21/2018	Granted - (G)

ABV12189BGO1	Bulgaria - (BG)	15721089.9	4/23/2015	3134430	3/21/2018	Granted - (G)
ABV12189BRO1	Brazil - (BR)	BR1120160245156	4/23/2015	BR1120160245156	3/31/2020	Granted - (G)
ABV12189CAO1	Canada - (CA)	2946402	4/23/2015			Filed - (F)
ABV12189CHO1	Switzerland - (CH)	15721089.9	4/23/2015	3134430	3/21/2018	Granted - (G)
ABV12189CLO1	Chile - (CL)	02683-2016	4/23/2015			Filed - (F)
ABV12189CND1	China - (CN)	202010767219.X	8/3/2020			Filed - (F)
ABV12189CNO1	China - (CN)	201580031858.7	4/23/2015	201580031858.7	9/1/2020	Granted - (G)
ABV12189COO1	Colombia - (CO)	NC2016/0003862	4/23/2015	34041	8/13/2018	Granted - (G)
ABV12189CRO1	Costa Rica - (CR)	2016-0516	4/23/2015			Filed - (F)
ABV12189CYO1	Cyprus - (CY)	15721089.9	4/23/2015	3134430	3/21/2018	Granted - (G)
ABV12189CZO1	Czechia - (CZ)	15721089.9	4/23/2015	3134430	3/21/2018	Granted - (G)
ABV12189DEO1	Germany - (DE)	15721089.9	4/23/2015	602015009124.8	3/21/2018	Granted - (G)
ABV12189DKO1	Denmark - (DK)	15721089.9	4/23/2015	3134430	3/21/2018	Granted - (G)
ABV12189DOO1	Dominican Republic - (DO)	P2016-0284	4/23/2015			Filed - (F)
ABV12189ECO1	Ecuador - (EC)	IEPI-2016-89579	4/23/2015			Filed - (F)
ABV12189EO1	Estonia - (EE)	15721089.9	4/23/2015	3134430	3/21/2018	Granted - (G)
ABV12189EPD1	European Patent Convention - (EP)	18155146.6	2/5/2018			Filed - (F)
ABV12189EPO1	European Patent Convention - (EP)	15721089.9	4/23/2015	3134430	3/21/2018	Granted - (G)
ABV12189ESO1	Spain - (ES)	15721089.9	4/23/2015	3134430	3/21/2018	Granted - (G)
ABV12189FIO1	Finland - (FI)	15721089.9	4/23/2015	3134430	3/21/2018	Granted - (G)
ABV12189FRO1	France - (FR)	15721089.9	4/23/2015	3134430	3/21/2018	Granted - (G)
ABV12189GBO1	United Kingdom of Great Britain and Northern Ireland - (GB)	15721089.9	4/23/2015	3134430	3/21/2018	Granted - (G)

ABV12189GCO1	Gulf Cooperation Council - (GC)	2015/29284	4/23/2015	GC0009979	7/1/2019	Granted - (G)
ABV12189GRO1	Greece - (GR)	20180401586	4/23/2015	3096074	3/21/2018	Granted - (G)
ABV12189GTO1	Guatemala - (GT)	A-2016-000224	4/23/2015			Filed - (F)
ABV12189HKO1	Hong Kong - (HK)	17108814.8	9/1/2017	1235072	8/24/2018	Granted - (G)
ABV12189HKO2	Hong Kong - (HK)	19119950.4	2/25/2019			Filed - (F)
ABV12189HRO1	Croatia - (HR)	P20180950T	4/23/2015	P20180950	3/21/2018	Granted - (G)
ABV12189HUO1	Hungary - (HU)	15721089.9	4/23/2015	3134430	3/21/2018	Granted - (G)
ABV12189IDO1	Indonesia - (ID)	P00201607579	4/23/2015	IDP000059187	5/27/2019	Granted - (G)
ABV12189IEO1	Ireland - (IE)	15721089.9	4/23/2015	3134430	3/21/2018	Granted - (G)
ABV12189ILO1	Israel - (IL)	248244	4/23/2015	248244	7/1/2020	Granted - (G)
ABV12189INO1	India - (IN)	201617038061	4/23/2015			Filed - (F)
ABV12189ISO1	Iceland - (IS)	15721089.9	4/23/2015	3134430	3/21/2018	Granted - (G)
ABV12189ITO1	Italy - (IT)	502018000015517	4/23/2015	3134430	3/21/2018	Granted - (G)
ABV12189JPD1	Japan - (JP)	2019-082671	4/24/2019	6714751	6/9/2020	Granted - (G)
ABV12189JPO1	Japan - (JP)	2016-564068	4/23/2015	6523331	5/10/2019	Granted - (G)
ABV12189KRO1	Korea, Republic of - (KR)	10-2016-7032819	4/23/2015	10-2079919	2/17/2020	Granted - (G)
ABV12189LIO1	Liechtenstein - (LI)	15721089.9	4/23/2015	3134430	3/21/2018	Granted - (G)
ABV12189LTO1	Lithuania - (LT)	15721089.9	4/23/2015	3134430	3/21/2018	Granted - (G)
ABV12189LUO1	Luxembourg - (LU)	15721089.9	4/23/2015	3134430	3/21/2018	Granted - (G)
ABV12189LVO1	Latvia - (LV)	15721089.9	4/23/2015	3134430	3/21/2018	Granted - (G)

ABV12189MAO1	Morocco - (MA)	39770	4/23/2015	39770	3/21/2018	Granted - (G)
ABV12189MCO1	Monaco - (MC)	15721089.9	4/23/2015	3134430	3/21/2018	Granted - (G)
ABV12189MEO1	Montenegro - (ME)	P-115/2018	4/23/2015	3134430	3/21/2018	Granted - (G)
ABV12189MKO1	North Macedonia - (MK)	P-2018/245	4/23/2015	908664	3/21/2018	Granted - (G)
ABV12189MTO1	Malta - (MT)	15721089.9	4/23/2015	3134430	3/21/2018	Granted - (G)
ABV12189MXO1	Mexico - (MX)	MX/a/2016/013858	4/23/2015	371851	11/15/2019	Granted - (G)
ABV12189MYO1	Malaysia - (MY)	P12016703814	4/23/2015			Filed - (F)
ABV12189NLO1	Netherlands - (NL)	15721089.9	4/23/2015	3134430	3/21/2018	Granted - (G)
ABV12189NOO1	Norway - (NO)	15721089.9	4/23/2015	3134430	3/21/2018	Granted - (G)
ABV12189NZD1	New Zealand - (NZ)	761611	2/11/2020			Filed - (F)
ABV12189NZD2	New Zealand - (NZ)	761612	2/11/2020			Filed - (F)
ABV12189NZO1	New Zealand - (NZ)	725476	4/23/2015			Filed - (F)
ABV12189PAO1	Panama - (PA)	91386-01	4/23/2015	91386-01	3/14/2019	Granted - (G)
ABV12189PEO1	Peru - (PE)	002016-2016	4/23/2015	10452	12/23/2020	Granted - (G)
ABV12189PHD1	Philippines - (PH)	1-2020-500377	2/26/2020			Filed - (F)
ABV12189PHO1	Philippines - (PH)	1-2016-502079	4/23/2015	1-2016-502079	6/2/2020	Granted - (G)
ABV12189PKO1	Pakistan - (PK)	232/2015	4/23/2015	143261	6/15/2020	Granted - (G)
ABV12189PLO1	Poland - (PL)	15721089.9	4/23/2015	3134430	3/21/2018	Granted - (G)
ABV12189PTO1	Portugal - (PT)	15721089.9	4/23/2015	3134430	3/21/2018	Granted - (G)
ABV12189ROO1	Romania - (RO)	15721089.9	4/23/2015	3134430	3/21/2018	Granted - (G)
ABV12189RSO1	Serbia - (RS)	P-2018/0450	4/23/2015	57153	3/21/2018	Granted - (G)

ABV12189RUO1	Russian Federation - (RU)	2016145608	4/23/2015	2699285	9/4/2019	Granted - (G)
ABV12189SEO1	Sweden - (SE)	15721089.9	4/23/2015	3134430	3/21/2018	Granted - (G)
ABV12189SGD1	Singapore - (SG)	10201806465T	7/30/2018			Filed - (F)
ABV12189SGO1	Singapore - (SG)	11201608767X	4/23/2015	11201608767X	8/14/2018	Granted - (G)
ABV12189SIO1	Slovenia - (SI)	201530223	4/23/2015	3134430	3/21/2018	Granted - (G)
ABV12189SKO1	Slovakia - (SK)	15721089.9	4/23/2015	3134430	3/21/2018	Granted - (G)
ABV12189SMO1	San Marino - (SM)	SM-T-201800286	4/23/2015	3134430	3/21/2018	Granted - (G)
ABV12189THO1	Thailand - (TH)	1601006350	4/23/2015			Filed - (F)
ABV12189TRO1	Turkey - (TR)	15721089.9	4/23/2015	TR201806912T4	3/21/2018	Granted - (G)
ABV12189TWD1	Taiwan (Province of China) - (TW)	109106778	3/2/2020			Filed - (F)
ABV12189TWO1	Taiwan (Province of China) - (TW)	104113087	4/23/2015	1683825	2/1/2020	Granted - (G)
ABV12189UAO1	Ukraine - (UA)	a201611802	4/23/2015	118286	12/26/2018	Granted - (G)
ABV12189USC2	United States of America - (US)	16/993569	8/14/2020			Filed - (F)
ABV12189USO1	United States of America - (US)	14/694358	4/23/2015	9908927	3/6/2018	Granted - (G)
ABV12189VNO1	Vietnam - (VN)	1-2016-04436	4/23/2015			Filed - (F)
ABV12189ZAO1	South Africa - (ZA)	2016/06978	4/23/2015	2016/06978	12/20/2017	Granted - (G)
ABV12212EPO1	European Patent Convention - (EP)	16736610.3	5/25/2016			Filed - (F)
ABV12212USO1	United States of America - (US)	15/164317	5/25/2016	10047051	8/14/2018	Granted - (G)
ABV12221ARO1	Argentina - (AR)	20160102165	7/15/2016			Filed - (F)
ABV12221AUO1	Australia - (AU)	2016293444	7/14/2016	2016293444	7/30/2020	Granted - (G)
ABV12221BRO1	Brazil - (BR)	BR1120180006491	7/14/2016			Filed - (F)
ABV12221CAO1	Canada - (CA)	2991273	7/14/2016			Filed - (F)
ABV12221CLO1	Chile - (CL)	00130-2018	7/14/2016			Filed - (F)

ABV12221CNO1	China - (CN)	201680053240.5	7/14/2016			Filed - (F)
ABV12221COO1	Colombia - (CO)	NC2018/0000413	7/14/2016	36385	11/5/2019	Granted - (G)
ABV12221CRO1	Costa Rica - (CR)	2018-0086	7/14/2016			Filed - (F)
ABV12221DEO1	Germany - (DE)	16739584.7	7/14/2016	602016026429.3	12/18/2019	Granted - (G)
ABV12221DOO1	Dominican Republic - (DO)	P2018-0020	7/14/2016			Filed - (F)
ABV12221ECO1	Ecuador - (EC)	IEPI-2018-8905	7/14/2016			Filed - (F)
ABV12221EPO1	European Patent Convention - (EP)	16739584.7	7/14/2016	3322697	12/18/2019	Granted - (G)
ABV12221ESO1	Spain - (ES)	16739584.7	7/14/2016	3322697	12/18/2019	Granted - (G)
ABV12221FRO1	France - (FR)	16739584.7	7/14/2016	3322697	12/18/2019	Granted - (G)
ABV12221GBO1	United Kingdom of Great Britain and Northern Ireland - (GB)	16739584.7	7/14/2016	3322697	12/18/2019	Granted - (G)
ABV12221GCO1	Gulf Cooperation Council - (GC)	2016/31723	7/17/2016			Filed - (F)
ABV12221GTO1	Guatemala - (GT)	A-2018-000023	7/14/2016			Filed - (F)
ABV12221IDO1	Indonesia - (ID)	P00201801162	7/14/2016	IDP000075763	4/1/2021	Granted - (G)
ABV12221ILD1	Israel - (IL)	274112	4/21/2020			Filed - (F)
ABV12221ILO1	Israel - (IL)	256851	7/14/2016	256851	9/1/2020	Granted - (G)
ABV12221INO1	India - (IN)	201817004854	7/14/2016			Filed - (F)
ABV12221ITO1	Italy - (IT)	502020000044812	7/14/2016	3322697	12/18/2019	Granted - (G)
ABV12221JPO1	Japan - (JP)	2017-568146	7/14/2016	6781720	10/20/2020	Granted - (G)
ABV12221KRO1	Korea, Republic of - (KR)	10-2018-7004637	7/14/2016			Filed - (F)
ABV12221MXO1	Mexico - (MX)	MX/a/2018/000688	7/14/2016	374537	8/25/2020	Granted - (G)
ABV12221MYO1	Malaysia - (MY)	P12018700126	7/14/2016			Filed - (F)
ABV12221NZO1	New Zealand - (NZ)	738813	7/14/2016			Filed - (F)
ABV12221PAO1	Panama - (PA)	91950-01	7/14/2016	91950-01	11/14/2019	Granted - (G)
ABV12221PEO1	Peru - (PE)	000074-2018	7/14/2016			Filed - (F)

ABV12221PHO1	Philippines - (PH)	1-2018-500088	7/14/2016			Filed - (F)
ABV12221PKO1	Pakistan - (PK)	429/2016	7/14/2016			Filed - (F)
ABV12221RUO1	Russian Federation - (RU)	2018105684	7/14/2016	2744766	3/15/2021	Granted - (G)
ABV12221SGO1	Singapore - (SG)	112018003735	7/14/2016			Filed - (F)
ABV12221THO1	Thailand - (TH)	1801000278	7/14/2016			Filed - (F)
ABV12221TWO1	Taiwan (Province of China) - (TW)	105122493	7/15/2016	1712597	12/11/2020	Granted - (G)
ABV12221UAO1	Ukraine - (UA)	a201801497	7/14/2016	122794	1/6/2021	Granted - (G)
ABV12221USO1	United States of America - (US)	15/205512	7/8/2016	9840513	12/12/2017	Granted - (G)
ABV12221UYO1	Uruguay - (UY)	36796	7/15/2016			Filed - (F)
ABV12221VNO1	Vietnam - (VN)	1-2018-00607	7/14/2016			Filed - (F)
ABV12221ZAO1	South Africa - (ZA)	2018/00541	7/14/2016	2018/00541	9/25/2019	Granted - (G)
ABV12239ATO1	Austria - (AT)	16788232.3	10/7/2016	E1298572	8/5/2020	Granted - (G)
ABV12239AUO1	Australia - (AU)	2016333856	10/7/2016			Filed - (F)
ABV12239BEO1	Belgium - (BE)	16788232.3	10/7/2016	3359541	8/5/2020	Granted - (G)
ABV12239BRO1	Brazil - (BR)	BR1120180071617	10/7/2016			Filed - (F)
ABV12239CAO1	Canada - (CA)	3001096	10/7/2016			Filed - (F)
ABV12239CHO1	Switzerland - (CH)	16788232.3	10/7/2016	3359541	8/5/2020	Granted - (G)
ABV12239CNO1	China - (CN)	201680069459.4	10/7/2016	201680069459.4	1/5/2021	Granted - (G)
ABV12239CYO1	Cyprus - (CY)	16788232.3	10/7/2016	3359541	8/5/2020	Granted - (G)
ABV12239CZO1	Czechia - (CZ)	16788232.3	10/7/2016	3359541	8/5/2020	Granted - (G)
ABV12239DEO1	Germany - (DE)	16788232.3	10/7/2016	602016041461.9	8/5/2020	Granted - (G)
ABV12239DKO1	Denmark - (DK)	16788232.3	10/7/2016	3359541	8/5/2020	Granted - (G)

ABV12239EP01	European Patent Convention - (EP)	16788232.3	10/7/2016	3359541	8/5/2020	Granted - (G)
ABV12239ES01	Spain - (ES)	16788232.3	10/7/2016	3359541	8/5/2020	Granted - (G)
ABV12239FI01	Finland - (FI)	16788232.3	10/7/2016	3359541	8/5/2020	Granted - (G)
ABV12239FR01	France - (FR)	16788232.3	10/7/2016	3359541	8/5/2020	Granted - (G)
ABV12239GB01	United Kingdom of Great Britain and Northern Ireland - (GB)	16788232.3	10/7/2016	3359541	8/5/2020	Granted - (G)
ABV12239GR01	Greece - (GR)	20200403042	10/7/2016	3105398	8/5/2020	Granted - (G)
ABV12239HR01	Croatia - (HR)	P20201618	10/7/2016	P20201618	8/5/2020	Granted - (G)
ABV12239HU01	Hungary - (HU)	E16788232	10/7/2016	E051067	8/5/2020	Granted - (G)
ABV12239IE01	Ireland - (IE)	16788232.3	10/7/2016	3359541	8/5/2020	Granted - (G)
ABV12239IS01	Iceland - (IS)	16788232.3	10/7/2016	3359541	8/5/2020	Granted - (G)
ABV12239IT01	Italy - (IT)	502020000104914	10/7/2016	3359541	8/5/2020	Granted - (G)
ABV12239JP01	Japan - (JP)	2018-517444	10/7/2016	6779992	10/16/2020	Granted - (G)
ABV12239LI01	Liechtenstein - (LI)	16788232.3	10/7/2016	3359541	8/5/2020	Granted - (G)
ABV12239LT01	Lithuania - (LT)	16788232.3	10/7/2016	3359541	8/5/2020	Granted - (G)
ABV12239LU01	Luxembourg - (LU)	16788232.3	10/7/2016	3359541	8/5/2020	Granted - (G)
ABV12239LV01	Latvia - (LV)	16788232.3	10/7/2016	3359541	8/5/2020	Granted - (G)
ABV12239MC01	Monaco - (MC)	16788232.3	10/7/2016	3359541	8/5/2020	Granted - (G)
ABV12239MX01	Mexico - (MX)	MX/a/2018/004359	10/7/2016	379276	3/23/2021	Granted - (G)

ABV12239NLO1	Netherlands - (NL)	16788232.3	10/7/2016	3359541	8/5/2020	Granted - (G)
ABV12239NOO1	Norway - (NO)	16788232.3	10/7/2016	3359541	8/5/2020	Granted - (G)
ABV12239PLO1	Poland - (PL)	16788232.3	10/7/2016	3359541	8/5/2020	Granted - (G)
ABV12239PTO1	Portugal - (PT)	16788232.3	10/7/2016	3359541	8/5/2020	Granted - (G)
ABV12239SEO1	Sweden - (SE)	16788232.3	10/7/2016	3359541	8/5/2020	Granted - (G)
ABV12239SIO1	Slovenia - (SI)	201630965	10/7/2016	3359541	8/5/2020	Granted - (G)
ABV12239TRO1	Turkey - (TR)	16788232.3	10/7/2016	TR20201729714	8/5/2020	Granted - (G)
ABV12239USC1	United States of America - (US)	15/843917	12/15/2017	10259810	4/16/2019	Granted - (G)
ABV12239USC3	United States of America - (US)	16/444495	6/18/2019	10647717	5/12/2020	Granted - (G)
ABV12239USO1	United States of America - (US)	15/287911	10/7/2016	9890158	2/13/2018	Granted - (G)
ABV12301ALO1	Albania - (AL)	AL/P/2020/0441	5/24/2017	9505	4/22/2020	Granted - (G)
ABV12301ARO1	Argentina - (AR)	20170101516	6/2/2017			Filed - (F)
ABV12301ATO1	Austria - (AT)	17728272.0	5/24/2017	E1259930	4/22/2020	Granted - (G)
ABV12301AUO1	Australia - (AU)	2017273215	5/24/2017			Filed - (F)
ABV12301BEO1	Belgium - (BE)	17728272.0	5/24/2017	3464282	4/22/2020	Granted - (G)
ABV12301BGO1	Bulgaria - (BG)	17728272.0	5/24/2017	3464282	4/22/2020	Granted - (G)
ABV12301BRO1	Brazil - (BR)	BR1120180748153	5/24/2017			Filed - (F)
ABV12301CAO1	Canada - (CA)	3022216	5/24/2017			Filed - (F)
ABV12301CHO1	Switzerland - (CH)	17728272.0	5/24/2017	3464282	4/22/2020	Granted - (G)
ABV12301CLO1	Chile - (CL)	03323-2018	5/24/2017			Filed - (F)
ABV12301CNO1	China - (CN)	201780033214.0	5/24/2017			Filed - (F)

ABV12301COO1	Colombia - (CO)	NC2018/0012171	5/24/2017	37569	8/10/2020	Granted - (G)
ABV12301CRO1	Costa Rica - (CR)	2018-0547	5/24/2017			Filed - (F)
ABV12301CVO1	Cyprus - (CY)	17728272.0	5/24/2017	3464282	4/22/2020	Granted - (G)
ABV12301CZO1	Czechia - (CZ)	17728272.0	5/24/2017	3464282	4/22/2020	Granted - (G)
ABV12301DEO1	Germany - (DE)	17728272.0	5/24/2017	602017015260.9	4/22/2020	Granted - (G)
ABV12301DKO1	Denmark - (DK)	17728272.0	5/24/2017	3464282	4/22/2020	Granted - (G)
ABV12301DOO1	Dominican Republic - (DO)	P2018-0257	5/24/2017			Filed - (F)
ABV12301ECO1	Ecuador - (EC)	SENADI-2018-94790	5/24/2017			Filed - (F)
ABV12301EOO1	Estonia - (EE)	17728272.0	5/24/2017	3464282	4/22/2020	Granted - (G)
ABV12301EPO1	European Patent Convention - (EP)	17728272.0	5/24/2017	3464282	4/22/2020	Granted - (G)
ABV12301ESO1	Spain - (ES)	17728272.0	5/24/2017	3464282	4/22/2020	Granted - (G)
ABV12301FIO1	Finland - (FI)	17728272.0	5/24/2017	3464282	4/22/2020	Granted - (G)
ABV12301FRO1	France - (FR)	17728272.0	5/24/2017	3464282	4/22/2020	Granted - (G)
ABV12301GBO1	United Kingdom of Great Britain and Northern Ireland - (GB)	17728272.0	5/24/2017	3464282	4/22/2020	Granted - (G)
ABV12301GCO1	Gulf Cooperation Council - (GC)	2017/33490	6/1/2017			Filed - (F)
ABV12301GRO1	Greece - (GR)	20200402018	5/24/2017	3104342	4/22/2020	Granted - (G)
ABV12301GTO1	Guatemala - (GT)	A-2018-000211	5/24/2017			Filed - (F)
ABV12301HKO1	Hong Kong - (HK)	19130172.0	9/25/2019	40006841	3/5/2021	Granted - (G)
ABV12301HRO1	Croatia - (HR)	P20201068	5/24/2017	P20201068	4/22/2020	Granted - (G)
ABV12301HUO1	Hungary - (HU)	17728272.0	5/24/2017	E050248	4/22/2020	Granted - (G)
ABV12301IDO1	Indonesia - (ID)	P00201811081	5/24/2017			Filed - (F)

ABV12301IEO1	Ireland - (IE)	17728272.0	5/24/2017	3464282	4/22/2020	Granted - (G)
ABV12301ILO1	Israel - (IL)	262415	5/24/2017			Filed - (F)
ABV12301INO1	India - (IN)	201817048664	5/24/2017			Filed - (F)
ABV12301ISO1	Iceland - (IS)	17728272.0	5/24/2017	3464282	4/22/2020	Granted - (G)
ABV12301ITO1	Italy - (IT)	50202000069358	5/24/2017	3464282	4/22/2020	Granted - (G)
ABV12301IPO1	Japan - (JP)	2018-552704	5/24/2017			Filed - (F)
ABV12301KRO1	Korea, Republic of - (KR)	10-2018-7031861	5/24/2017			Filed - (F)
ABV12301LIO1	Liechtenstein - (LI)	17728272.0	5/24/2017	3464282	4/22/2020	Granted - (G)
ABV12301LTO1	Lithuania - (LT)	17728272.0	5/24/2017	3464282	4/22/2020	Granted - (G)
ABV12301LUO1	Luxembourg - (LU)	17728272.0	5/24/2017	3464282	4/22/2020	Granted - (G)
ABV12301LVO1	Latvia - (LV)	17728272.0	5/24/2017	3464282	4/22/2020	Granted - (G)
ABV12301MCO1	Monaco - (MC)	17728272.0	5/24/2017	3464282	4/22/2020	Granted - (G)
ABV12301MKO1	North Macedonia - (MK)	P-2020/498	5/24/2017	3464282	4/22/2020	Granted - (G)
ABV12301MTO1	Malta - (MT)	17728272.0	5/24/2017	3464282	4/22/2020	Granted - (G)
ABV12301MXO1	Mexico - (MX)	MX/a/2018/014758	5/24/2017			Filed - (F)
ABV12301MYO1	Malaysia - (MY)	P12018703798	5/24/2017			Filed - (F)
ABV12301NLO1	Netherlands - (NL)	17728272.0	5/24/2017	3464282	4/22/2020	Granted - (G)
ABV12301NOO1	Norway - (NO)	17728272.0	5/24/2017	3464282	4/22/2020	Granted - (G)
ABV12301NZO1	New Zealand - (NZ)	747222	5/24/2017			Filed - (F)
ABV12301PAO1	Panama - (PA)	92450-01	5/24/2017			Filed - (F)
ABV12301PEO1	Peru - (PE)	003091-2018	5/24/2017			Filed - (F)
ABV12301PHO1	Philippines - (PH)	1-2018-502534	5/24/2017	1-2018-502534	6/25/2020	Granted - (G)
ABV12301PKO1	Pakistan - (PK)	309/2017	5/30/2017			Filed - (F)

ABV12301PLO1	Poland - (PL)	17728272.0	5/24/2017	3464282	4/22/2020	Granted - (G)
ABV12301PTO1	Portugal - (PT)	17728272.0	5/24/2017	3464282	4/22/2020	Granted - (G)
ABV12301ROO1	Romania - (RO)	EP/01892/2020	5/24/2017	3464282	4/22/2020	Granted - (G)
ABV12301RSO1	Serbia - (RS)	P-2020/0829	5/24/2017	60574	4/22/2020	Granted - (G)
ABV12301RUO1	Russian Federation - (RU)	2018138707	5/24/2017		4/22/2020	Granted - (G)
ABV12301SEO1	Sweden - (SE)	17728272.0	5/24/2017	3464282	4/22/2020	Granted - (G)
ABV12301SGO1	Singapore - (SG)	11201808842V	5/24/2017	11201808842V	2/23/2021	Granted - (G)
ABV12301SIO1	Slovenia - (SI)	201730320	5/24/2017	3464282	4/22/2020	Granted - (G)
ABV12301SKO1	Slovakia - (SK)	17728272.0	5/24/2017	3464282	4/22/2020	Granted - (G)
ABV12301SMO1	San Marino - (SM)	SM-T-202000394	5/24/2017	3464282	4/22/2020	Granted - (G)
ABV12301THO1	Thailand - (TH)	1801006986	5/24/2017			Granted - (G)
ABV12301TRO1	Turkey - (TR)	2020/11315	5/24/2017	TR202011315T4	4/22/2020	Granted - (G)
ABV12301TWO1	Taiwan (Province of China) - (TW)	106118418	6/3/2017			Granted - (G)
ABV12301UAO1	Ukraine - (UA)	a201812705	5/24/2017			Granted - (G)
ABV12301USC1	United States of America - (US)	16/165662	10/19/2018	10604515	3/31/2020	Granted - (G)
ABV12301USO1	United States of America - (US)	15/602892	5/23/2017	10138227	11/27/2018	Granted - (G)
ABV12301UYO1	Uruguay - (UY)	37272	6/2/2017			Granted - (G)
ABV12301VNO1	Vietnam - (VN)	1-2018-05431	5/24/2017			Granted - (G)
ABV12301ZAO1	South Africa - (ZA)	2018/08423	5/24/2017	2018/08423	8/28/2019	Granted - (G)
ABV12315EPO1	European Patent Convention - (EP)	17794414.7	10/4/2017			Granted - (G)
ABV12315USO1	United States of America - (US)	15/723896	10/3/2017	10399940	9/3/2019	Granted - (G)
ABV12356USO1	United States of America - (US)	15/902802	2/22/2018	10428017	10/1/2019	Granted - (G)

ABV12356USO2	United States of America - (US)	15/903928	2/23/2018			Filed - (F)
ABV12400ALO1	Albania - (AL)	AL/P/2021/0044	9/13/2018	3681864	10/28/2020	Granted - (G)
ABV12400ATO1	Austria - (AT)	18779798.0	9/13/2018	E1328079	10/28/2020	Granted - (G)
ABV12400AUO1	Australia - (AU)	2018332512	9/13/2018			Filed - (F)
ABV12400BAO1	Bosnia and Herzegovina - (BA)	E03740	9/13/2018	3681864	10/28/2020	Granted - (G)
ABV12400BEO1	Belgium - (BE)	18779798.0	9/13/2018	3681864	10/28/2020	Granted - (G)
ABV12400BGO1	Bulgaria - (BG)	18779798.0	9/13/2018	3681864	10/28/2020	Granted - (G)
ABV12400BRO1	Brazil - (BR)	BR1120200051020	9/13/2018			Filed - (F)
ABV12400CAO1	Canada - (CA)	3074945	9/13/2018			Filed - (F)
ABV12400CHO1	Switzerland - (CH)	18779798.0	9/13/2018	3681864	10/28/2020	Granted - (G)
ABV12400CLO1	Chile - (CL)	0664-2020	9/13/2018			Filed - (F)
ABV12400CNO1	China - (CN)	201880073855.3	9/13/2018			Filed - (F)
ABV12400COO1	Colombia - (CO)	NC2020/0004249	9/13/2018			Filed - (F)
ABV12400CRO1	Costa Rica - (CR)	2020-0157	9/13/2018			Filed - (F)
ABV12400CYO1	Cyprus - (CY)	18779798.0	9/13/2018	3681864	10/28/2020	Granted - (G)
ABV12400CZO1	Czechia - (CZ)	18779798.0	9/13/2018	3681864	10/28/2020	Granted - (G)
ABV12400DEO1	Germany - (DE)	18779798.0	9/13/2018	602018009206.4	10/28/2020	Granted - (G)
ABV12400DKO1	Denmark - (DK)	18779798.0	9/13/2018	3681864	10/28/2020	Granted - (G)
ABV12400DOO1	Dominican Republic - (DO)	P2020-0057	9/13/2018			Filed - (F)
ABV12400ECO1	Ecuador - (EC)	SENADI-2020-21913	9/13/2018			Filed - (F)
ABV12400EOO1	Estonia - (EE)	18779798.0	9/13/2018	3681864	10/28/2020	Granted - (G)
ABV12400EPD1	European Patent Convention - (EP)	20183402.5	7/1/2020	3736270	5/5/2021	Granted - (G)
ABV12400EPD2	European Patent Convention - (EP)	20183405.8	7/1/2020	3736267	5/5/2021	Granted - (G)

ABV12400EPD3	European Patent Convention - (EP)	21164249.1	3/23/2021		Filed - (F)
ABV12400EPO1	European Patent Convention - (EP)	18779798.0	9/13/2018	3681864	Granted - (G)
ABV12400ESO1	Spain - (ES)	18779798.0	9/13/2018	3681864	Granted - (G)
ABV12400FIO1	Finland - (FI)	18779798.0	9/13/2018	3681864	Granted - (G)
ABV12400FRO1	France - (FR)	18779798.0	9/13/2018	3681864	Granted - (G)
ABV12400GBO1	United Kingdom of Great Britain and Northern Ireland - (GB)	18779798.0	9/13/2018	3681864	Granted - (G)
ABV12400GRO1	Greece - (GR)	20210400224	9/13/2018	3106178	Granted - (G)
ABV12400GTO1	Guatemala - (GT)	A-2020-000040	9/13/2018		Filed - (F)
ABV12400HKO1	Hong Kong - (HK)	62020019755.1	11/10/2020		Filed - (F)
ABV12400HKO2	Hong Kong - (HK)	42020021751.1	12/9/2020		Filed - (F)
ABV12400HKO3	Hong Kong - (HK)	42020022349.3	12/18/2020		Filed - (F)
ABV12400HRO1	Croatia - (HR)	P20210099	9/13/2018	P20210099	Granted - (G)
ABV12400HUO1	Hungary - (HU)	18779798.0	9/13/2018	E052873	Granted - (G)
ABV12400IDO1	Indonesia - (ID)	P00202002777	9/13/2018		Filed - (F)
ABV12400IEO1	Ireland - (IE)	18779798.0	9/13/2018	3681864	Granted - (G)
ABV12400ILO1	Israel - (IL)	273163	9/13/2018		Filed - (F)
ABV12400INO1	India - (IN)	202017016002	9/13/2018		Filed - (F)
ABV12400ISO1	Iceland - (IS)	18779798.0	9/13/2018	3681864	Granted - (G)
ABV12400ITO1	Italy - (IT)	502021000019616	9/13/2018	3681864	Granted - (G)
ABV12400JPO1	Japan - (JP)	2020-537292	9/13/2018		Filed - (F)
ABV12400KRO1	Korea, Republic of - (KR)	10-2020-7010867	9/13/2018		Filed - (F)
ABV12400LIO1	Liechtenstein - (LI)	18779798.0	9/13/2018	3681864	Granted - (G)
ABV12400LTO1	Lithuania - (LT)	18779798.0	9/13/2018	3681864	Granted - (G)

ABV12400LUO1	Luxembourg - (LU)	18779798.0	9/13/2018	3681864	10/28/2020	Granted - (G)
ABV12400LVO1	Latvia - (LV)	18779798.0	9/13/2018	3681864	10/28/2020	Granted - (G)
ABV12400MAO1	Morocco - (MA)	18779798.0	9/13/2018	3681864	10/28/2020	Granted - (G)
ABV12400MCO1	Monaco - (MC)	18779798.0	9/13/2018	3681864	10/28/2020	Granted - (G)
ABV12400MDO1	Moldova - (MD)	6788	9/13/2018	3681864	10/28/2020	Granted - (G)
ABV12400MEO1	Montenegro - (ME)	P-27/2021	9/13/2018	3681864	10/28/2020	Granted - (G)
ABV12400MKO1	North Macedonia - (MK)	P-2021/050	9/13/2018	3681864	10/28/2020	Granted - (G)
ABV12400MTO1	Malta - (MT)	18779798.0	9/13/2018	3681864	10/28/2020	Granted - (G)
ABV12400MXO1	Mexico - (MX)	MX/a/2020/002806	9/13/2018			Filed - (F)
ABV12400MYO1	Malaysia - (MY)	P12020001287	9/13/2018			Filed - (F)
ABV12400NLO1	Netherlands - (NL)	18779798.0	9/13/2018	3681864	10/28/2020	Granted - (G)
ABV12400NOO1	Norway - (NO)	18779798.0	9/13/2018	3681864	10/28/2020	Granted - (G)
ABV12400NZO1	New Zealand - (NZ)	763163	9/13/2018			Filed - (F)
ABV12400PAO1	Panama - (PA)	93034-01	9/13/2018			Filed - (F)
ABV12400PEO1	Peru - (PE)	000670-2020/DIN	9/13/2018			Filed - (F)
ABV12400PHO1	Philippines - (PH)	1-2020-500509	9/13/2018			Filed - (F)
ABV12400PLO1	Poland - (PL)	18779798.0	9/13/2018	3681864	10/28/2020	Granted - (G)
ABV12400PTO1	Portugal - (PT)	18779798.0	9/13/2018	3681864	10/28/2020	Granted - (G)
ABV12400ROO1	Romania - (RO)	18779798.0	9/13/2018	3681864	10/28/2020	Granted - (G)
ABV12400RSO1	Serbia - (RS)	P-2021/0082	9/13/2018	3681864	10/28/2020	Granted - (G)
ABV12400RUO1	Russian Federation - (RU)	2020113350	9/13/2018			Filed - (F)
ABV12400SEO1	Sweden - (SE)	18779798.0	9/13/2018	3681864	10/28/2020	Granted - (G)

ABV12400SGO1	Singapore - (SG)	11202002101R	9/13/2018			Filed - (F)
ABV12400SIO1	Slovenia - (SI)	201830193	9/13/2018	3681864	10/28/2020	Granted - (G)
ABV12400SKO1	Slovakia - (SK)	18779798.0	9/13/2018	3681864	10/28/2020	Granted - (G)
ABV12400SMO1	San Marino - (SM)	SM-T-202100140	9/13/2018	3681864	10/28/2020	Granted - (G)
ABV12400THO1	Thailand - (TH)	2001001464	9/13/2018			Filed - (F)
ABV12400TNO1	Tunisia - (TN)	2021/0015	9/13/2018	3681864	10/28/2020	Granted - (G)
ABV12400TRO1	Turkey - (TR)	18779798.0	9/13/2018	TR20210116514	10/28/2020	Granted - (G)
ABV12400UAO1	Ukraine - (UA)	a202002356	9/13/2018			Filed - (F)
ABV12400USC1	United States of America - (US)	16/878416	5/19/2020	10844041	11/24/2020	Granted - (G)
ABV12400USC2	United States of America - (US)	16/878421	5/19/2020	10844042	11/24/2020	Granted - (G)
ABV12400USC3	United States of America - (US)	16/878430	5/19/2020	10829473	11/10/2020	Granted - (G)
ABV12400USC4	United States of America - (US)	16/878468	5/19/2020	10981890	4/20/2021	Granted - (G)
ABV12400USC5	United States of America - (US)	17/231482	4/15/2021			Filed - (F)
ABV12400USO1	United States of America - (US)	16/129458	9/12/2018	10988454	4/27/2021	Granted - (G)
ABV12400VNO1	Vietnam - (VN)	1-2020-02091	9/13/2018			Filed - (F)
ABV12400ZAO1	South Africa - (ZA)	2020/02363	9/13/2018			Filed - (F)
ABV12449EPO1	European Patent Convention - (EP)	20177749.7	6/2/2020			Filed - (F)
ABV12449USO1	United States of America - (US)	16/890035	6/2/2020			Filed - (F)

PATENT

REEL: 063100 FRAME: 0049

RECORDED: 03/15/2023